Daniel C Bruhm
Overview
Explore the profile of Daniel C Bruhm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruhm D, Vulpescu N, Foda Z, Phallen J, Scharpf R, Velculescu V
Nat Rev Cancer
. 2025 Mar;
PMID: 40038442
Genomic analyses of cell-free DNA (cfDNA) in plasma are enabling noninvasive blood-based biomarker approaches to cancer detection and disease monitoring. Current approaches for identification of circulating tumour DNA typically use...
2.
Medina J, Annapragada A, Lof P, Short S, Bartolomucci A, Mathios D, et al.
Cancer Discov
. 2024 Sep;
15(1):105-118.
PMID: 39345137
There is an unmet need for effective ovarian cancer screening and diagnostic approaches that enable earlier-stage cancer detection and increased overall survival. We have developed a high-performing accessible approach that...
3.
Noe M, Mathios D, Annapragada A, Koul S, Foda Z, Medina J, et al.
Nat Commun
. 2024 Aug;
15(1):6690.
PMID: 39107309
Circulating cell-free DNA (cfDNA) is emerging as an avenue for cancer detection, but the characteristics of cfDNA fragmentation in the blood are poorly understood. We evaluate the effect of DNA...
4.
Annapragada A, Niknafs N, White J, Bruhm D, Cherry C, Medina J, et al.
Sci Transl Med
. 2024 Mar;
16(738):eadj9283.
PMID: 38478628
Genetic changes in repetitive sequences are a hallmark of cancer and other diseases, but characterizing these has been challenging using standard sequencing approaches. We developed a de novo kmer finding...
5.
Bruhm D, Mathios D, Foda Z, Annapragada A, Medina J, Adleff V, et al.
Nat Genet
. 2023 Jul;
55(8):1301-1310.
PMID: 37500728
Somatic mutations are a hallmark of tumorigenesis and may be useful for non-invasive diagnosis of cancer. We analyzed whole-genome sequencing data from 2,511 individuals in the Pan-Cancer Analysis of Whole...
6.
Leal A, Mathios D, Jakubowski D, Johansen J, Lau A, Wu T, et al.
Chest
. 2023 Apr;
164(4):1019-1027.
PMID: 37116747
Background: The diagnostic workup of individuals suspected of having lung cancer can be complex and protracted because conventional symptoms of lung cancer have low specificity and sensitivity. Research Question: Among...
7.
Foda Z, Annapragada A, Boyapati K, Bruhm D, Vulpescu N, Medina J, et al.
Cancer Discov
. 2022 Nov;
13(3):616-631.
PMID: 36399356
Significance: There is a great need for accessible and sensitive screening approaches for HCC worldwide. We have developed an approach for examining genome-wide cfDNA fragmentation features to provide a high-performing...
8.
Mathios D, Johansen J, Cristiano S, Medina J, Phallen J, Larsen K, et al.
Nat Commun
. 2021 Aug;
12(1):5060.
PMID: 34417454
Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for cancer detection and intervention. Here, we use a machine learning model for detecting tumor-derived cfDNA through genome-wide analyses of...
9.
Anagnostou V, Bruhm D, Niknafs N, White J, Shao X, Sidhom J, et al.
Cell Rep Med
. 2020 Dec;
1(8):100139.
PMID: 33294860
In this study, we incorporate analyses of genome-wide sequence and structural alterations with pre- and on-therapy transcriptomic and T cell repertoire features in immunotherapy-naive melanoma patients treated with immune checkpoint...
10.
Anagnostou V, Niknafs N, Marrone K, Bruhm D, White J, Naidoo J, et al.
Nat Cancer
. 2020 Sep;
1(1):99-111.
PMID: 32984843
Despite progress in immunotherapy, identifying patients that respond has remained a challenge. Through analysis of whole-exome and targeted sequence data from 5,449 tumors, we found a significant correlation between tumor...